English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells

MPS-Authors
/persons/resource/persons78492

Penzes,  Kinga
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons77719

Baumann,  Christine
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78812

Ullrich,  Axel
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons130605

Torka,  Robert
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Penzes, K., Baumann, C., Szabadkai, I., Orfi, L., Keri, G., Ullrich, A., et al. (2014). Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. CANCER BIOLOGY & THERAPY, 15(11), 1571-1582. doi:10.4161/15384047.2014.956634.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0025-736C-3
Abstract
Blocking the migration of metastatic cancer cells is a major goal in the therapy of cancer. The receptor tyrosine kinase AXL is one of the main triggers for cancer cell migration in neoplasia of breast, colon, skin, thyroid and prostate. In our study we analyzed the effect of AXL inhibition on cell motility and viability in triple negative breast cancer cell lines overexpressing AXL. Thereby we reveal that the compound BMS777607, exhibiting the lowest IC50 values for inhibition of AXL kinase activity in the studied cell lines, attenuates cell motility to a lower extent than the kinase inhibitors MPCD84111 and SKI606. By analyzing the target kinases of MPCD84111 and SKI606 with kinase profiling assays we identified Lyn, a Src family kinase, as a target of both compounds. Knockdown of Lyn and the migration-related CRK-associated substrate (p130Cas), had a significant inhibitory effect on cell migration. Taken together, our findings highlight the importance of combinatorial or multikinase inhibition of non-receptor tyrosine kinases and AXL receptor tyrosine kinase in the therapy of triple negative breast cancer.